CA1259074C - - Google Patents

Info

Publication number
CA1259074C
CA1259074C CA 470917 CA470917A CA1259074C CA 1259074 C CA1259074 C CA 1259074C CA 470917 CA470917 CA 470917 CA 470917 A CA470917 A CA 470917A CA 1259074 C CA1259074 C CA 1259074C
Authority
CA
Canada
Prior art keywords
conpound
bronchodilator
useful
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA 470917
Other languages
English (en)
Other versions
CA1258859A (fr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to CA000562864A priority Critical patent/CA1259074A/fr
Publication of CA1258859A publication Critical patent/CA1258859A/fr
Application granted granted Critical
Publication of CA1259074C publication Critical patent/CA1259074C/xx
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA000470917A 1983-12-24 1984-12-21 Derive de carbostyrile, et sa preparation Expired CA1258859A (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000562864A CA1259074A (fr) 1983-12-24 1988-03-29 Derive de carbostyril et procede de preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838334494A GB8334494D0 (en) 1983-12-24 1983-12-24 Carbostyril derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA000562864A Division CA1259074A (fr) 1983-12-24 1988-03-29 Derive de carbostyril et procede de preparation

Publications (2)

Publication Number Publication Date
CA1258859A CA1258859A (fr) 1989-08-29
CA1259074C true CA1259074C (fr) 1989-09-05

Family

ID=10553866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000470917A Expired CA1258859A (fr) 1983-12-24 1984-12-21 Derive de carbostyrile, et sa preparation

Country Status (10)

Country Link
US (2) US4579854A (fr)
EP (1) EP0147719B1 (fr)
JP (2) JPS60208965A (fr)
AT (1) ATE44954T1 (fr)
CA (1) CA1258859A (fr)
DE (1) DE3479119D1 (fr)
GB (1) GB8334494D0 (fr)
HK (1) HK89790A (fr)
MY (1) MY101891A (fr)
SG (1) SG75290G (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677112A (en) * 1984-02-02 1987-06-30 Warner-Lambert Company 1,2,3,4-tetrahydro-2-oxo-8-quinolineacetic and -propanoic acids and derivatives as cognition activators
US4687776A (en) * 1986-10-24 1987-08-18 Warner-Lambert Company Drug stabilization
DE69420832T2 (de) * 1993-10-21 2000-01-13 Otsuka Pharma Co Ltd Die Verwendung von Carbostyrilderivaten zur Herstellung eines Arzneimittels zur Hemmung der Produktion von Interleukin-8
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
EP0969816B1 (fr) 1997-03-20 2004-12-15 Schering Corporation Preparation d'agglomerats de poudre
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
SI1273292T1 (en) * 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
MEP30108A (en) * 2002-03-01 2010-06-10 Chiesi Farmaceutici S P Formoterol superfine formulation
EP1507754A1 (fr) 2002-05-28 2005-02-23 Theravance, Inc. Agonistes du recepteur adrenergique beta 2 alcoxy aryle
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ATE526967T1 (de) * 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
EP1654001A2 (fr) * 2003-08-05 2006-05-10 Boehringer Ingelheim International GmbH Medicament pour inhalation comprenant des steroides et un betamimetique
US20050059643A1 (en) * 2003-08-05 2005-03-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a steroid and a betamimetic
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1595531A1 (fr) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1574501A1 (fr) * 2004-03-11 2005-09-14 Pfizer Limited Dérivés de quinoléinone, compositions pharmaceutiques les contenant et leur usage
WO2005092861A1 (fr) * 2004-03-11 2005-10-06 Pfizer Limited Derives de quinolinone compositions pharmaceutiques contenant ces derives et utilisation de celles-ci
AR048339A1 (es) * 2004-03-24 2006-04-19 Chiesi Farma Spa Monoclorhidrato de 8- hidroxi-5-((1r)) -1- hidroxi-2- (((1r)-2 ( 4-metoxifenil) -1- metiletil) amino ) eti l) -2 (1h) - quinolinona en form acristalina y el proceso para su preparacion
US7307076B2 (en) * 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
AU2005252226A1 (en) 2004-06-03 2005-12-22 Theravance, Inc. Diamine beta2 adrenergic receptor agonists
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
WO2006031556A2 (fr) 2004-09-10 2006-03-23 Theravance. Inc. Composes d'arylaniline a substitution amidine
JP2008534611A (ja) 2005-03-30 2008-08-28 シェーリング コーポレイション 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
JP2008542332A (ja) * 2005-05-31 2008-11-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患治療用新規医薬組成物
AU2006275137A1 (en) * 2005-08-01 2007-02-08 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
BRPI0615064A2 (pt) * 2005-08-26 2011-05-03 Astrazeneca Ab combinação de compostos que pode ser usada no tratamento de doenças respiratórias, especialmente, doença pulmonar obstrutiva crÈnica (dpoc) e asma
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20090250058A1 (en) * 2006-07-14 2009-10-08 Astrazeneca Ab Inhalation System and Delivery Device for the Administration of a Drug in the Form of Dry Powder
CN101553493B (zh) 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
CA2667962A1 (fr) 2006-10-30 2008-05-08 Novartis Ag Composes heterocycliques en tant qu'agents anti-inflammatoires
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CA2672446A1 (fr) 2006-12-19 2008-06-26 Astrazeneca Ab Derives quinuclidinol utilises en tant qu'antagonistes du recepteur muscarinique
EP1953143A1 (fr) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Processus de préparation de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY30916A1 (es) * 2007-02-15 2008-09-30 Argenta Discovery Ltd Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros
WO2008104781A1 (fr) 2007-02-28 2008-09-04 Cipla Limited Procédé de préparation d'isomères de carmotérol
CA2608561A1 (fr) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Support d'accessoires de deflecteur pour motocyclette
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100598A1 (fr) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2116537A1 (fr) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorphe de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
EP2116536A1 (fr) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Forme cristalline de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
BRPI0912657A2 (pt) * 2008-05-13 2016-01-26 Astrazeneca Ab produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
CA2723981A1 (fr) * 2008-05-13 2009-11-19 Astrazeneca Ab Derives de quinuclidine utilises comme antagonistes des recepteurs muscariniques m3
CA2721065C (fr) 2008-05-27 2016-09-27 Astrazeneca Ab Derives de phenoxypyridinylamide et leur utilisation comme inhibiteurs de pde4
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
WO2010067102A1 (fr) 2008-12-09 2010-06-17 Astrazeneca Ab Dérivés de diazaspiro[5.5]undécane et composés associés utilisés comme antagonistes des récepteurs muscariniques et agonistes des récepteurs bêta adrénergiques dans le traitement des affections pulmonaires
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (fr) 2009-03-12 2010-09-15 Almirall, S.A. Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
WO2011015289A1 (fr) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. Hémi-fumarate de 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2- (4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1h)-quinolinone
WO2011061527A1 (fr) 2009-11-17 2011-05-26 Astrazeneca Ab Combinaisons qui comprennent un modulateur du récepteur glucocorticoïde, destinées au traitement de maladies respiratoires
EP2360147A1 (fr) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Procédé de préparation de particules crystallines d'un sel de 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
WO2011136754A1 (fr) 2010-04-26 2011-11-03 Mahmut Bilgic Médicament mis au point pour le traitement de maladies respiratoires
EP2563364A1 (fr) 2010-04-26 2013-03-06 Mahmut Bilgic Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
WO2011136752A1 (fr) 2010-04-26 2011-11-03 Mahmut Bilgic Composition pharmaceutique combinée comprenant du carmotérol et du ciclésonide pour le traitement de maladies respiratoires
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
GB2484977A (en) * 2010-10-29 2012-05-02 Biocopea Ltd Treatment of a Th-1 mediated disease
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
WO2013011999A1 (fr) * 2011-07-20 2013-01-24 株式会社カネカ Procédé pour produire un dérivé optiquement actif de 2-méthylproline
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
WO2013077830A1 (fr) 2011-11-25 2013-05-30 Mahmut Bilgic Associations actives sur le plan synergique contenant du roflumilast et du carmotérol
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
CZ306252B6 (cs) * 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE354279B (fr) * 1969-06-13 1973-03-05 Draco Ab
JPS5156464A (ja) * 1974-11-11 1976-05-18 Otsuka Pharma Co Ltd Karubosuchirirujudotaino seizoho
US4022776A (en) * 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
JPS6026784B2 (ja) * 1975-04-29 1985-06-25 樋口 佳成 新規カルボスチリル誘導体
JPS52283A (en) * 1975-06-23 1977-01-05 Otsuka Pharmaceut Co Ltd Process for preparation of carbostyril derivatives
JPS5913510B2 (ja) * 1975-12-26 1984-03-30 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
JPS609713B2 (ja) * 1976-10-08 1985-03-12 大塚製薬株式会社 カルボスチリル誘導体
JPS5913510A (ja) * 1982-07-14 1984-01-24 Kotobuki Sangyo Kk 冷却誘導案内装置

Also Published As

Publication number Publication date
USRE33024E (en) 1989-08-15
CA1258859A (fr) 1989-08-29
EP0147719B1 (fr) 1989-07-26
DE3479119D1 (en) 1989-08-31
ATE44954T1 (de) 1989-08-15
EP0147719A3 (en) 1986-06-25
JPS60208965A (ja) 1985-10-21
JPH0446950B2 (fr) 1992-07-31
JPS6354362A (ja) 1988-03-08
SG75290G (en) 1990-11-23
US4579854A (en) 1986-04-01
MY101891A (en) 1992-02-15
EP0147719A2 (fr) 1985-07-10
HK89790A (en) 1990-11-09
GB8334494D0 (en) 1984-02-01

Similar Documents

Publication Publication Date Title
CA1259074C (fr)
AU589387B2 (en) Bicyclic heterocyclic piperazine derivatives
UA7083A1 (uk) Спосіб одержання похідних 1,4-дігідропірідіна або їх кислотно-адітивних солей
AU589427B2 (en) Pyridonecarboxylic acid derivatives and process for their preparation
PT83104A (en) Novel guanidinomethylbenzoic acid derivatives
PT77370A (en) Process for preparing new pyrazolo <3,4-b> piridine derivatives and pharmaceutical preparations containing the same
ES8606330A1 (es) Procedimiento para preparar derivados de acidos quinolincar-boxilicos
ES8703460A1 (es) Un procedimiento para preparar aminoacil-ladanos
UA6330A1 (uk) Спосіб одержання похідних бензаміда
EP0207497A3 (fr) Dérivé d'acide quinolonecarboxylique et son procédé de préparation
EP0331078A3 (fr) Procédé de préparation de dérivés optiquement actifs de l'acide 4-oxo-benzopyranne-2-carboxylique et leurs intermédiaires
ZA855594B (en) Naphthyl analogs of mevalonolactone and derivatives thereof,processes for their production and their use
CS884386A2 (en) Zpusob vyroby novych soli aryloxypropanolaminu s kyselinou difenyloctovou
ES532124A0 (es) Un procedimiento para preparar derivados de acido 4, 7-dihidropirazolo (3, 4-b) piridin-5-carboxilico
ES8502076A1 (es) Procedimiento para la preparacion de acido 3b-(3-carboxipropioniloxi)-ursa-9(11),12-dien-28-oico
HU182118B (en) Process for preparing 7-oxo-4-thia-1-aza-aicyclo /3,2,0/ /heptane derivatives as beta-lactamase inhibitors
YU104986A (en) Process for obtaining penem derivatives
AU560656B2 (en) N-acyl-3-amino-1,2,3,4-tetrahydroquinolines
ES546646A0 (es) Un procedimiento para preparar un compuesto relacionado con arfamenina
YU44618B (en) Process for preparation of derivatives (1,2,4-triazolyle)-2-propanol
ES8304925A1 (es) Un procedimiento para la preparacion de nuevos derivados del acido &-glutamil-diaminopimelilo.
PT80905A (en) Process for preparing 2,5-pyrrolidindione derivatives useful as antiarrhythmic agents
YU44619B (en) Process for preparation of derivatives (1,2,4-triazolyle)-2-propanol
JPS5788177A (en) Theobromine derivative and its preparation
ES8606375A1 (es) Un procedimiento para preparar un derivado de aminoprpilaminobleomicina

Legal Events

Date Code Title Description
MKEX Expiry